Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Instil Bio Inc. (TIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/24/2025: TIL (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 110.03% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 111.07M USD | Price to earnings Ratio - | 1Y Target Price 113.67 |
Price to earnings Ratio - | 1Y Target Price 113.67 | ||
Volume (30-day avg) 90905 | Beta 1.74 | 52 Weeks Range 9.62 - 92.00 | Updated Date 04/2/2025 |
52 Weeks Range 9.62 - 92.00 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.39 |
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate -3.65 | Actual -1.08 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.72% | Return on Equity (TTM) -37.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84641596 | Price to Sales(TTM) 55329.79 |
Enterprise Value 84641596 | Price to Sales(TTM) 55329.79 | ||
Enterprise Value to Revenue 43213.95 | Enterprise Value to EBITDA 0.62 | Shares Outstanding 6525890 | Shares Floating 2670001 |
Shares Outstanding 6525890 | Shares Floating 2670001 | ||
Percent Insiders 12.82 | Percent Institutions 80.38 |
Analyst Ratings
Rating 4.25 | Target Price 114 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Instil Bio Inc.
Company Overview
History and Background
Instil Bio Inc. is a biopharmaceutical company focused on developing tumor-infiltrating lymphocyte (TIL) therapies for the treatment of cancer. Founded in 2018, the company aims to harness the power of the patient's own immune system to fight solid tumors. Initial efforts focused on advancing a TIL therapy for melanoma before expanding to other cancers.
Core Business Areas
- TIL Therapy Development: Instil Bio focuses on developing and commercializing TIL therapies, which involve isolating, expanding, and re-infusing a patient's own immune cells to target cancer cells.
Leadership and Structure
Instil Bio's leadership team includes seasoned executives with experience in biopharmaceuticals and cell therapies. The organizational structure supports research and development, clinical trials, and manufacturing operations.
Top Products and Market Share
Key Offerings
- ITIL-168 (Lifileucel): Lifileucel is Instil Bio's lead TIL therapy candidate for advanced melanoma. The FDA has accepted the BLA filing for lifileucel with a PDUFA date of November 25, 2024. Competitors include other cell therapies and checkpoint inhibitors from companies like Iovance Biotherapeutics (IOVA) and Merck (MRK).
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, with significant investment and research focused on developing novel immunotherapies for cancer. TIL therapy represents a promising approach for treating solid tumors that have not responded to other treatments.
Positioning
Instil Bio is positioned as a key player in the TIL therapy space, with a focus on developing differentiated and scalable manufacturing processes. Their potential competitive advantage lies in improved potency and efficacy compared to earlier generation TIL therapies.
Total Addressable Market (TAM)
The TAM for TIL therapies is estimated to be in the billions of dollars, targeting various solid tumor indications. Instil Bio is positioned to capture a share of this market with its lead candidate and pipeline of TIL therapies.
Upturn SWOT Analysis
Strengths
- Proprietary TIL manufacturing platform
- Experienced leadership team
- Promising clinical data for ITIL-168
- Strong intellectual property position
Weaknesses
- Reliance on a single lead product candidate
- High manufacturing costs associated with cell therapies
- Regulatory and commercialization risks
- Cash burn rate
Opportunities
- Expansion into new cancer indications
- Partnerships with larger pharmaceutical companies
- Advancements in TIL technology and manufacturing
- Potential for accelerated regulatory approval
Threats
- Competition from other cell therapy companies
- Clinical trial failures
- Changes in regulatory landscape
- Reimbursement challenges for cell therapies
Competitors and Market Share
Key Competitors
- IOVA
- MRK
- BMY
Competitive Landscape
Instil Bio is competing in a crowded market with established pharmaceutical companies and other cell therapy developers. Its competitive advantage will depend on the efficacy, safety, and manufacturability of its TIL therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Instil Bio's historical growth is characterized by advancements in its clinical pipeline and expansion of its manufacturing capabilities.
Future Projections: Future growth is dependent on the successful development and commercialization of its TIL therapies. Analyst estimates vary, but generally project significant revenue potential if ITIL-168 is approved.
Recent Initiatives: Recent initiatives include the advancement of ITIL-168 through clinical trials, expansion of its pipeline to include other TIL therapies, and investment in its manufacturing platform.
Summary
Instil Bio is a clinical-stage biopharmaceutical company focused on TIL therapies, particularly ITIL-168 for melanoma, which is currently under FDA review. While its technology holds promise, Instil Bio faces significant challenges including competition from established players and the high costs and complexities of cell therapy manufacturing. Its success hinges on positive clinical trial outcomes and successful commercialization. Maintaining a strong cash position is crucial to fund ongoing research and development activities.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
IOVA
Iovance Biotherapeutics Inc
IOVA
Iovance Biotherapeutics Inc
LGND
Ligand Pharmaceuticals Incorporated
LGND
Ligand Pharmaceuticals Incorporated
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Instil Bio Inc.
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-03-19 | Chairman & CEO Mr. Bronson Crouch | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://instilbio.com |
Full time employees 14 | Website https://instilbio.com | ||
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It also develops AXN-2510/IMM2510 that is in Phase 1b/2clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. ImmuneOnco is conducting a Phase 1 open label trial in China of AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors that have failed prior therapies, including triple-negative breast cancer, or TNBC, squamous non-small cell lung cancer (squamous NSCLC), hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors including soft tissue sarcomas and thymic cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.